Tamoxifen in patients with advanced pancreatic adenocarcinoma
Abstract:
Estrogen and somatostatin receptors have been found in pancreatic carcinoma cells, The growth of pancreatic carcinomas has been shown to be inhibited by various endocrine treatments. In view of these findings, a well known anti-estrogen tamoxifen has been used, both as a single agent and in combination with other agents, in clinical trials in patients with unresectable carcinoma of the exocrine pancreas. The impact on survival of tamoxifen in patients with advanced pancreatic adenocarcinoma has been assessed among patients from the previously reported trials of tamoxifen as a single agent, and compared with the survival of patients treated with the synergistic combination of intravenous Onconase plus oral tamoxifen. While a few patients treated with tamoxifen as a single agent may survive for prolonged period of time, the significance of such results remains uncertain in view of the lack of significant survival difference between patients treated with tamoxifen vs. untreated controls in prospectively randomized trials, and vis a vis clearly multifactorial determination of survival. On the other hand, the synergistic combinations of agents that demonstrate favorable toxicity profiles may offer significant survival advantage, at least in some patients with advanced pancreatic cancer.
Insights
Tamoxifen showed uncertain survival benefits for pancreatic cancer patients. Combination therapies, however, may offer significant survival advantages in advanced pancreatic adenocarcinoma.
Area of Science:
- Oncology
- Endocrinology
Background:
- Pancreatic carcinoma cells express estrogen and somatostatin receptors.
- Endocrine treatments have demonstrated potential in inhibiting pancreatic cancer growth.
Purpose of the Study:
- To evaluate the impact of tamoxifen, an anti-estrogen agent, on survival in patients with advanced pancreatic adenocarcinoma.
- To compare the efficacy of tamoxifen as a single agent versus its combination with intravenous Onconase.
Main Methods:
- Clinical trials involving patients with unresectable exocrine pancreatic cancer.
- Assessment of survival data for patients treated with tamoxifen alone.
- Comparison of survival outcomes between tamoxifen monotherapy and combination therapy (Onconase plus tamoxifen).
Main Results:
- Tamoxifen as a single agent showed uncertain survival benefits, with no significant difference compared to untreated controls in randomized trials.
- Prolonged survival was observed in a few patients on tamoxifen monotherapy, but its significance is unclear.
- Synergistic combination therapies exhibited favorable toxicity profiles and potential for significant survival advantage in some advanced pancreatic cancer patients.
Conclusions:
- Tamoxifen monotherapy's role in improving survival for advanced pancreatic cancer is uncertain.
- Combination therapies, particularly with favorable toxicity profiles, may offer a promising strategy for improving survival in advanced pancreatic cancer.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers